Pacific Biosciences Of California (PACB) Non-Current Debt (2010 - 2022)

Pacific Biosciences Of California has reported Non-Current Debt for 12 years, with the latest figure at $500000.0 in Q4 2022.

• For the quarter ending Q4 2022, Non-Current Debt fell 78.26% year-over-year to $500000.0; the trailing twelve-month figure through Dec 2022 stood at $500000.0 (down 78.26% YoY), and the FY2022 full-year result was $500000.0, down 78.26% from the prior year.
• Non-Current Debt for Q4 2022 stood at $500000.0, down from $2.3 million in the prior quarter.
• The five-year high for Non-Current Debt was $15.8 million in Q4 2019, with the low at $500000.0 in Q4 2022.
• Average Non-Current Debt over 4 years is $10.8 million, with a median of $14.1 million recorded in 2018.
• Year-over-year, Non-Current Debt soared 37.57% in 2018 and plunged 78.26% in 2022.
• Tracing PACB's Non-Current Debt over 4 years: stood at $14.7 million in 2018, then increased by 7.78% to $15.8 million in 2019, then plunged by 85.44% to $2.3 million in 2021, then sank by 78.26% to $500000.0 in 2022.
• The last three Non-Current Debt figures came in at $500000.0 (Q4 2022), $2.3 million (Q4 2021), and $15.8 million (Q4 2019), per Business Quant data.

Peer Comparison